Skip to search boxSkip to navigationSkip to main content

Antisense inhibition of hMLH1 is not sufficient for loss of DNA mismatch repair function in the HCT116+chromosome 3 cell line

  • Dharam P. Chauhan
    ,
  • Qinghua Yang
    ,
  • John M. Carethers
    ,
  • Giancarlo Marra
    ,
  • Christina L. Chang
    ,
  • Sherman M Chamberlain
  • University of California at San Diego
    ,
  • Department of Veterans Affairs
    ,
Scholary Output:
Contribution to journal
Article
Peer-review

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

We have reported that transfer of chromosome 3 (Chr3) containing a single wild-type copy of the hMLH1 gene into HCT116 colon cancer cells, a cell line deficient in DNA mismatch repair (MMR) activity attributable to inactivating hMLH1 mutations, corrects all of the aspects of the MMR repair-deficient phenotype. We inhibited the expression of the wild-type hMLH1 gene using antisense RNA in HCT116+Chr3 cells to determine if this would result in reversion to the MMR-deficient phenotype. Despite profound inhibition of hMLH1 expression, DNA MMR activity and alkylation sensitivity were not impaired in the antisense-transfected HCT116+Chr3 cells. Additionally, arrest of the cell cycle at the G2 phase with alkylation damage occurs in these cells, a phenotype associated with MMR proficiency. These results indicate that even with a reduction in the expression of hMLH1 protein below the limits of detection by Western blotting, DNA MMR activity remained fully functional (by direct DNA MMR activity assay). We would speculate that hMLH1 is expressed in substantially greater abundance than would be minimally necessary for DNA MMR and that minor reductions in the expression of this protein would not be sufficient to permit DNA MMR dysfunction. Alternatively, Chr3 may contain a second hMLH1 homologue that might overlap with the function of hMLH1.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 3827-3831 (5 pages)

Journal (Volume, Issue Number)

Clinical Cancer Research (Volume 6, Issue 10)

Publication milestones

  • Published - 2000

Publication status

Published - 2000

ISSN

1078-0432

Publication IDs

  • Scopus: 0033760356
  • PubMed: 11051225

Publication metrics

Metrics

SciVal
FWCI
0.18
SciVal
Author count
7
SciVal
citations
8
SciVal
Paper percentile
52
Fractional count
1
Fractional count
0.14
Fractional count
6
Fractional count
0.86
Fractional count
1
Fractional count
1
Scopus
citations

PlumX

Citation count
7
Captures
12

Funding Details

FunderFunding number
NIDDK
K08DK002433